Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice
- 21 September 2023
- journal article
- research article
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319 (Pt 1) , 117183
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize PrimingImmunity, 2017
- CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancerOncogene, 2016
- Cyclin D1, cancer progression, and opportunities in cancer treatmentJournal of Molecular Medicine, 2016
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyAnnals of Oncology, 2016
- BuShenYiQi Formula strengthens Th1 response and suppresses Th2-Th17 responses in RSV-induced asthma exacerbated miceJournal of Ethnopharmacology, 2014
- TCMSP: a database of systems pharmacology for drug discovery from herbal medicinesJournal of Cheminformatics, 2014
- Mechanisms of Caspase Activation and Inhibition during ApoptosisMolecular Cell, 2002
- The CXC Chemokines Growth-regulated Oncogene (GRO) α, GROβ, GROγ, Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 ReceptorJournal of Biological Chemistry, 1996
- The Effect of Body Weight on Tumor Incidence and Carcinogenicity Testing in B6C3F1 Mice and F344 RatsFundamental and Applied Toxicology, 1995